ICIs targeting CTLA-4, PD-1 and PD-L1 have dramatically improved survival rates across diverse cancer types, including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), hepatocellular carcinoma, and triple negative breast cancer. Here, CD274 is linked to non-small cell lung carcinoma.